Hot Features
Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.
Allakos Inc is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases. The company's lead program, AK002, an antibody that targets Sig... Allakos Inc is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases. The company's lead program, AK002, an antibody that targets Siglec-8, an inhibitory receptor found on eosinophils and mast cells. In preclinical and clinical studies, AK002 has been shown to deplete eosinophils and inhibit mast cells. Mehr anzeigen
– Subcutaneously administered AK006 showed approximately 77% bioavailability and prolonged receptor occupancy on mast cells –– Subcutaneous AK006 was well-tolerated with a favorable safety profile...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.1243 | -11.8380952381 | 1.05 | 1.0501 | 0.7962 | 423167 | 0.91952891 | CS |
| 4 | -0.3643 | -28.2403100775 | 1.29 | 1.555 | 0.7962 | 606777 | 1.18899602 | CS |
| 12 | 0.2257 | 32.2428571429 | 0.7 | 1.555 | 0.535 | 686839 | 1.05454795 | CS |
| 26 | -0.5043 | -35.2657342657 | 1.43 | 1.555 | 0.535 | 624125 | 1.01023334 | CS |
| 52 | -0.8543 | -47.9943820225 | 1.78 | 3.405 | 0.535 | 872413 | 1.42021643 | CS |
| 156 | -79.3943 | -98.8474850598 | 80.32 | 86.95 | 0.535 | 1382964 | 5.92483128 | CS |
| 260 | -90.9743 | -98.9927094668 | 91.9 | 157.98 | 0.535 | 940427 | 16.72806203 | CS |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
